Serotonergic Dysfunction in Parkinson’s Disease Impulse Control Disorders
Overview
Impulse control disorders (ICDs) in Parkinson’s disease (PD) have traditionally been linked to dopaminergic dysfunction. Recent evidence highlights significant serotonergic alterations correlating with ICD severity and impulsivity subtypes, suggesting a more complex neurochemical basis.
Background
ICDs, including hypersexuality, binge eating, and compulsive gambling, are disruptive non-motor complications of PD. Historically, these behaviors were attributed to mesolimbic dopaminergic dysfunction driving reward-seeking and impaired inhibitory control. Emerging research indicates that serotonergic systems also play a critical role in modulating impulsivity and reward-based learning in PD patients with ICDs. Understanding these mechanisms is essential for developing targeted therapies beyond dopaminergic modulation.
Data Highlights
Measure
Finding
Presynaptic SERT binding
Elevated in posterior putamen and pallidum in PDICD+ patients
Postsynaptic 5-HT2A receptor availability
Increased in bilateral SMA, precentral gyrus, right DLPFC in PDICD+ patients
Correlation
Serotonergic alterations correlate with ICD severity and impulsivity subtypes
Key Findings
PD patients with ICDs show elevated serotonin transporter binding in striatal regions, indicating altered serotonergic innervation or transporter expression.
Increased 5-HT2A receptor availability in motor and prefrontal cortical areas suggests compensatory receptor upregulation linked to serotonergic deficits.
Serotonergic dysfunction correlates with both action (motor) and decision (choice) impulsivity, which are anatomically dissociable.
Serotonergic alterations may predispose certain PD patients to more severe ICDs, supported by genetic associations with serotonin synthesis enzymes.
Findings support a model of ICD pathophysiology involving functional disconnection in cortico-striato-pallido-thalamic circuits beyond dopaminergic dysregulation.
Serotonin-based interventions and neuromodulation targeting inhibitory control circuits represent promising adjunctive therapeutic strategies.
Clinical Implications
Clinicians should consider serotonergic dysfunction as a contributing factor in PD-related ICDs, especially when dopaminergic dose adjustments fail to resolve symptoms. Personalized treatment approaches incorporating serotonin receptor modulators or neuromodulatory techniques targeting motor and prefrontal circuits may improve management of ICDs. Genetic screening for serotonergic pathway variants could identify patients at higher risk for severe ICDs, guiding precision medicine strategies.
Conclusion
This commentary underscores the importance of serotonergic systems in the pathophysiology of ICDs in Parkinson’s disease, expanding the traditional dopamine-centric view. Integrating serotonergic targets into therapeutic paradigms holds potential to enhance outcomes for affected patients.
